Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement

Abstract

Infliximab therapy resulted in a statistically significant improvement in % predicted FVC at Week 24. The clinical importance of this finding is not clear. The results of this Phase 2 clinical study support further evaluation of anti-TNF-alpha therapy in severe, chronic, symptomatic sarcoidosis.

Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring

“…Some experts advocate 6-12 mo of therapy, whereas others recommend consideration of lifelong treatment because of reports of relapse or sudden death. 83,84 Other immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil, or infliximab, have been used with some success for systemic sarcoidosis, [85][86][87][88][89][90][91] but data regarding their use in CS are quite limited.…”

TNFα blockade in human diseases: An overview of efficacy and safety

“…ETA was assessed in a preliminary trial of patients with progressive sarcoidosis, but the trial was stopped because of treatment failure in majority of participants [77]. A more recent phase 2 clinical trial using INF showed a statistically significant improvement in % predicted FVC at week 24, supporting further evaluation of anti-TNF therapy for sarcoidosis [78].…”

Infantile Onset Panniculitis with Uveitis and Systemic Granulomatosis: A New Clinicopathologic Entity

“…Anti-TNF monoclonal antibody therapy has been used successfully in granulomatous inflammatory diseases including Crohn's and adult sarcoidosis (11). In our experience, the administration of anti-TNF agents allowed better disease control with tapering of systemic cortico-steroids.…”